Better medicines demand better chemistry. At Arcus, we’re advancing validated biology with exceptional chemistry to create medicines that outperform existing standards of care and deliver meaningful improvements for patients with cancer and immune diseases.
In-house scientific expertise has been core to Arcus’s discovery group since its founding, and it creates biological synergies that span our oncology and immunology programs from cancers of high unmet need to common immune conditions affecting large patient populations.
Chemistry determines whether a molecule designed against a target becomes a differentiated treatment. Our chemists design molecules with exceptional potency and selectivity, optimized to redefine standards of care. This approach is producing investigational oral small molecule medicines built to work in the real world of a patient’s body, not just in the lab.
Biology identifies promising targets. We focus on validated mechanisms with strong clinical and scientific evidence, so we can accelerate the development of new medicines that we believe can improve upon existing treatments.
The greatest opportunities in medicine come from pairing validated biology with exceptional chemistry to deliver meaningful improvements for patients with cancer and immune diseases. It is why we hold every program to a single standard: the potential to outperform the current standard of care.
